Press Releases 2017-09-13T20:17:34+00:00

Press Releases

JAK Inhibitors Expected to Introduce Fierce Competition to Treatment Paradigms Across a Wide Range of Autoimmune Indications, Including Psoriatic Arthritis, Atopic Dermatitis, Ulcerative Colitis, and Lupus

Recent milestones include Pfizer’s Xeljanz approval for PsA in December, the pending review of Xeljanz in UC expected in mid-2018, and this week’s announcement by AbbVie that its JAK1 has been granted Breakthrough Therapy Designation by the FDA for atopic dermatitis. EXTON, Pa., January 10, 2017 /PRNewswire/ — On-going, independent research conducted by Spherix Global Insights over the past several years highlights expanding use of Pfizer’s JAK inhibitor Xeljanz (tofacitinib) in rheumatoid arthritis (RA), with momentum anticipated to continue. Over the past year, the Xeljanz user-base and rheumatologist reported satisfaction with the agent in RA has consistently increased. Additionally, over [...]

January 10, 2018|

Use of Monoclonal Antibody Disease-Modifying Therapies on the Rise in Multiple Sclerosis, Fueled Largely by the Introduction of Genentech’s Ocrevus

According to the most recent quarterly update from Spherix Global Insights, multiple sclerosis-focused neurologists report increased use of monoclonal antibody disease-modifying therapies and a recent chart audit of over 500 patients on monoclonal antibody disease-modifying therapy highlights important characteristics for patients being selected for this class of disease-modifying therapies Download Report Overview EXTON, Pa., January 10, 2018 /PRNewswire/ — With the April 2017 launch of Genentech’s Ocrevus, the monoclonal antibody (mAb) disease-modifying therapy (DMT) class share of DMT-treated multiple sclerosis (MS) patients has increased steadily over the past three consecutive quarters, according to neurologists’ self-reported prescribing behavior in the RealTime [...]

January 10, 2018|

With Ocrevus Uptake in Primary Progressive Multiple Sclerosis a Relative Lock, Genentech and US Neurologists are Increasingly Focused on Ocrevus Positioning in Relapsing Forms of Multiple Sclerosis

Swift uptake of Mylan’s generic glatiramer acetate 20mg and 40mg is being driven by perceptions of preferential payer coverage although a dispensed-as-written strategy for Teva’s Copaxone may be limiting greater conversion, according to a new report from Spherix Global Insights Download Report Overview EXTON, Pa., December 7, 2017 /PRNewswire/ — Seven months post-launch, the clear majority of US neurologists (n=103) have initiated at least one patient on Genentech’s Ocrevus, with the brand share being boosted by uptake in both relapsing remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) patients. Reflecting the great unmet need for PPMS treatments and [...]

December 7, 2017|

Eli Lilly’s Taltz Now Approved for Psoriatic Arthritis, Bringing Key Competition for Rival IL-17 Inhibitor, Novartis’ Cosentyx

According to Spherix Global Insights’ RealTime Dynamix™: Psoriatic Arthritis quarterly series, US rheumatologists have become increasingly familiar with Taltz as a potential treatment for PsA and are primed to adopt the newest IL-17 agent into their PsA armamentarium. Download Report Overview EXTON, Pa., December 4, 2017 /PRNewswire/ — Eli Lilly’s IL-17 inhibitor, Taltz (ixekizumab), received FDA approval for the treatment of adults with active psoriatic arthritis (PsA) on December 1, 2017. The new indication for the brand will bring increased competition to a market that has been bustling with recent change via a series of line extensions (BMS’ Orencia and [...]

December 4, 2017|

US Dermatologists Delighted with Sanofi/Regeneron’s Dupixent, but Increased Familiarity and Experience with Pfizer’s Eucrisa May be Breeding Contempt

According to a recent study conducted by Spherix Global Insights, US dermatologists (n=104) report significantly higher satisfaction with Dupixent than with any of the other approved agents for the treatment of atopic dermatitis, while Eucrisa garners the lowest satisfaction ratings. Download Report Overview EXTON, Pa., Nov. 30, 2017 /PRNewswire/ -- The most recent release of RealTime Dynamix™: Atopic Dermatitis reveals steady uptake of the newest atopic dermatitis launches, Dupixent and Eucrisa. Both agents have consistently enjoyed substantial user- and patient-base gains quarter over quarter since launching, with the vast majority of collaborating dermatologists reporting current clinical experience. Furthermore, projected use [...]

November 30, 2017|

Dermatologists’ Six Month Projections Reveal Janssen’s Tremfya Closing in on the IL-17 Inhibitors, Novartis’ Cosentyx and Eli Lilly’s Taltz, in Psoriasis

According to Spherix Global Insights' latest quarterly release of RealTime Dynamix™: Psoriasis, adoption of Tremfya as a psoriasis treatment is largely comparable to that of Taltz's at a similar post-launch timeframe. Download Report Overview EXTON, Pa., Nov. 29, 2017 /PRNewswire/ -- At approximately four months post-launch, over one-third of surveyed dermatologists (n=101) have prescribed Tremfya, a figure on par with uptake of Taltz at a similar post-launch fielding time. Current users of the IL-23 inhibitor cite that they most commonly initiate patients on the brand due to their severity and the perceived efficacy that Tremfya may offer. Furthermore, over half [...]

November 29, 2017|